Get started
Author

Isabel Garau

Observed names: I Garau, I. Garau
Observed institutions: Universidad Complutense de Madrid, University of Padua, Hospital Universitario La Paz, Instituto de Salud Carlos III, Asan Medical Center, Hospital Universitari Arnau de Vilanova, Hospital Clínico San Carlos, University of Ulsan, Hospital Universitario San Agustín, Hospital Son Llatzer, Escuela Nacional de Sanidad, Servei de Salut de les Illes Balears, Hospital Clínico Universitario de Valencia, Complejo Hospitalario Universitario de Santiago, Consorcio Hospitalario Provincial de Castellón, Hospital Universitario 12 De Octubre, Institut Català d'Oncologia, IPO Porto, Hospital Virgen de la Salud, Hospital Universitario Miguel Servet, Hospital Clínic de Barcelona, Hospital Arnau de Vilanova, Vall d'Hebron Hospital Universitari, Hospital Del Mar, Hospital Universitario Central de Asturias, Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Fuenlabrada, Hospital Universitari Sant Joan de Reus, Centro de Investigación Biomédica en Red de Cáncer, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Hospital Universitario Ramón y Cajal, GEICAM – Spanish Breast Cancer Group, Hospital Universitario Infanta Cristina, Complejo Hospitalario Universitario de Ferrol, Vall d'Hebron Institute of Oncology, Hospital San Agustín, Hospital San Agustín, Universitat de les Illes Balears
OpenAlex ID: A5031413640
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
2017 · Marco Colleoni, Weixiu Luo, et al. · The Lancet Oncology · 120
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
2020 · Eva Ciruelos, Patricia Villagrasa, et al. · Clinical Cancer Research · 114
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
2020 · Fara Brasó-Maristany, Gaia Griguolo, et al. · Nature Communications · 114
PDF
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
2017 · P. Nuciforo, T. Pascual, et al. · Annals of Oncology · 113
Recent Changes in Breast Cancer Incidence in Spain, 1980–2004
2009 · Marina Pollán, Roberto Pastor-Barriuso, et al. · JNCI Journal of the National Cancer Institute · 110
PDF
Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer
2009 · Jorge Sastre-Serra, Adamo Valle, et al. · Free Radical Biology and Medicine · 102
Variation in ‘standard care’ for breast cancer across Europe: A EUROCARE-3 high resolution study
2010 · Claudia Allemani, Hans Storm, et al. · European Journal of Cancer · 76
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
2021 · Rebecca Dent, Mafalda Oliveira, et al. · Breast Cancer Research and Treatment · 75
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
2021 · G. Griguolo, G. Serna, et al. · npj Precision Oncology · 58
Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain
2018 · I. Esteban, M. Vilaró, et al. · Psycho-Oncology · 38
Influence of stage at diagnosis on survival differences for rectal cancer in three European populations
1999 · E Monnet, J Faivre, et al. · British Journal of Cancer · 33
PDF
Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain
2010 · R. Marcos-Gragera, M. Pollán, et al. · Annals of Oncology · 26
PDF
The oxidative stress in breast tumors of postmenopausal women is ERα/ERβ ratio dependent
2013 · Jorge Sastre-Serra, Mercedes Nadal-Serrano, et al. · Free Radical Biology and Medicine · 23
Incidencia y mortalidad por cáncer en España. Patrones y tendencia
2000 · R Miñarro, RJ Black, et al. · Revista Española de Salud Pública · 20
PDF
Blood transfusion has no effect on colorectal cancer survival. A population-based study
1994 · I. Garau, E. Benito, et al. · European Journal of Cancer · 19
Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer
2019 · E Ciruelos, P Villagrasa, et al. · Cancer Research · 18
Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
2018 · Vanesa Ortega, Antonio Antón, et al. · Clinical Breast Cancer · 16
Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous
2016 · Sandro Barni, Beata Freier, et al. · Current Medical Research and Opinion · 11
Assessment of Feasibility of Workplace Health Promotion
2002 · Timo Partanen, Mauri Johansson, et al. · Preventive Medicine · 11
Actitudes de los trabajadores frente a los programas de promoción de la salud para la prevención del cáncer en el lugar del trabajo
2002 · M. Sala, G. Janer, et al. · Gaceta Sanitaria · 10
PDF
Comparability of colorectal cancer survival data in three European population-based registries.
1998 · E Monnet, J Faivre, et al. · PubMed · 10
Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
2017 · P. Nuciforo, A. Prat, et al. · Annals of Oncology · 9
PDF
Mejoría de la supervivencia de la poliposis adenomatosa familiar después del establecimiento de un registro
2007 · José Reyes Moreno, Daniel Ginard Vicens, et al. · Medicina Clínica · 9
Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial
2018 · E Ciruelos, P Villagrasa, et al. · Cancer Research · 7
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
2017 · P. Villagrasa Gonzalez, A. Prat, et al. · Annals of Oncology · 6
Works count: 59
Citation count: 1,168
H-index: 16
I10-index: 21
Year
Topic
Type